The firm will now be known as Alcami
AAIPharma Services (AAI)/Cambridge Major Laboratories (CML), a US-based provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, has a new name and identity.
The organisation will now be known as Alcami.
Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.
By providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami believes it has created a robust new outsourcing offering.
Alcami has recently made significant investment in additional capabilities and capacity for oral solid dose manufacturing, and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilisation capacity.
Additionally, Alcami will be relocating its current St Louis Analytical Testing Services to a new facility at the Cortex Innovation Centre in St Louis, MO, which provides innovative analytical testing solutions for new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals.
Alcami Chief Executive Stephan Kutzer said: 'With nearly 1,000 employees at seven sites in the US and Europe, these upgrades across our facilities, combined with enhancements in our quality, execution and customer focus, support the overall progress of our growth strategy as a contract services provider with a renewed commitment to meeting customer needs.'